Whale Large Capital
  • Politics
  • World News
  • Business
  • Investing
  • Politics
  • World News
  • Business
  • Investing

Whale Large Capital

Business

FDA officially authorizes Zyn nicotine pouches for sale following health review

by January 17, 2025
January 17, 2025
FDA officially authorizes Zyn nicotine pouches for sale following health review

The U.S. Food and Drug Administration formally authorized Zyn nicotine pouches for sale after conducting an ‘extensive scientific review’ about their safety.

In a release Thursday, the agency said it had found that the popular pouches posed lower risk of cancer and other serious health conditions compared with cigarettes, as well as in relation to other smokeless tobacco products.

The agency also found that the pouches even had the potential to benefit cigarette smokers amid evidence that they can get them to quit.

‘The data show that these nicotine pouch products meet that bar by benefiting adults who use cigarettes and/or smokeless tobacco products and completely switch to these products,” Matthew Farrelly, director of the office of science in the FDA’s Center for Tobacco Products, said in a statement. 

Zyn use has exploded in recent years in the wake of a viral online meme trend, even prompting a shortage last year. Yet the product had been operating in a legal gray area while it underwent official FDA review about its health effects and uptake among young users.

To that latter point, the FDA found that, so far, Zyn use among youths appeared to be relatively low, though it was continuing to monitor the trend.

A spokesperson for Philip Morris International Inc., which owns the U.S. rights to Zyn, did not immediately respond to a request for comment.

Swedish Match, the developer of Zyn, said in a statement, “The FDA’s authorization of all ZYN nicotine pouches currently marketed by Swedish Match in the U.S. is an important step to protect the public health by providing better alternatives to cigarettes and other traditional tobacco products for adults 21+.”

The Campaign for Tobacco-Free Kids slammed the FDA’s decision in a separate statement.

‘The FDA today has set a dangerous precedent that puts the nation’s kids at risk by authorizing the sale of 20 Zyn nicotine pouch products with flavors that clearly appeal to kids, including chill, citrus, cool mint and peppermint,’ it said.

‘The FDA’s decision is deeply troubling given the extensive scientific evidence that flavored tobacco products appeal to kids and the fact that nicotine pouches were the only category of tobacco product that saw an increase in youth use last year. The FDA is sanctioning a flavored tobacco product that is already increasing in popularity with kids and repeating the mistakes it made with Juul that resulted in the youth e-cigarette epidemic.’

In the release, the FDA emphasized that its findings about Zyn did not mean the products are ultimately safe or “FDA approved.”

‘There is no safe tobacco product,’ the agency said. ‘Youth should not use tobacco products and adults who do not use tobacco products should not start.’

This post appeared first on NBC NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
RNC chair Whatley vows to be ‘tip of the spear’ to protect Trump after coasting to reelection victory
next post
UnitedHealth CEO says U.S. health system ‘needs to function better’

You may also like

A flagging U.S. industry looks for new life...

July 18, 2025

Travis Kelce part of investor group aiming to...

October 24, 2025

IBM pledges $150 billion to boost U.S. tech...

April 29, 2025

Restaurant chain Hooters files for bankruptcy protection to enable founder-led...

April 1, 2025

Starbucks imposes new limits on what baristas can...

April 23, 2025

Netflix secures U.S. rights to the FIFA Women’s...

December 22, 2024

Cracker Barrel rebrand: Why companies retreat when faced...

August 29, 2025

Barry’s Bootcamp announces new investment as others exit...

January 14, 2025

Target calls price hikes a ‘very last resort’...

May 21, 2025

Coca-Cola takes on Olipop and Poppi with new...

February 19, 2025

    Subscribe today to receive exclusive access to all our retirement secrets and income strategies, including special financial news and updates from our experts. From time to time, our newsletters feature valuable insights and analysis on the latest financial trends. Don't miss out on these exclusive updates – join our subscription to stay informed!


    By opting in you agree to receive emails from us. Your information is secure and your privacy is protected.



    Latest

    • Israel hammers Iranian internal security command centers to open door to uprising

      March 4, 2026
    • Hegseth says the leader behind effort to assassinate Trump has been ‘hunted down and killed’ in Iran

      March 4, 2026
    • US submarine sinks Iranian warship by torpedo in a first since World War II

      March 4, 2026
    • Israel says fighter jet took down Iranian warplane, the first shootdown of its kind

      March 4, 2026
    • MIKE DAVIS: The unsung, but crucial foot soldiers in Trump’s war on fraud

      March 4, 2026
    • Former MLB star Mark Teixeira wins GOP primary in Texas congressional race

      March 4, 2026

    Categories

    • Business (853)
    • Investing (661)
    • Politics (7,797)
    • World News (3,213)

    Disclaimer: WhaleLargeCapital.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2026 whalelargecapital.com | All Rights Reserved